Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAutologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsProstate-Specific Membrane Antigen modulators
TargetsProstate-Specific Membrane AntigenT cell surface glycoprotein CD3
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesRoger Williams Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesRoger Williams Medical Center
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A